Edwards Lifesciences Corporation $EW Stock: Robeco Schweiz AG Grows Position

Key Points

• Robeco Schweiz AG increased its Edwards Lifesciences stake by 79.9% in the third quarter, bringing its holdings to 29,742 shares valued at approximately $2.57 million. Institutional investors collectively own 79.46% of the company.
• Wall Street analysts maintain a positive outlook, with a consensus “Moderate Buy” rating and an average price target of $100.27, above the stock’s reported opening price of $89.15.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus the $0.74 consensus and revenue of $1.74 billion. Revenue increased 13.6% year over year, while insiders sold 5,045 shares worth about $451,596 over the past 90 days.

Robeco Schweiz AG raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 79.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 29,742 shares of the medical research company's stock after purchasing an additional 13,213 shares during the period. Robeco Schweiz AG's holdings in Edwards Lifesciences were worth $2,567,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Signaturefd LLC grew its stake in shares of Edwards Lifesciences by 1.4% during the 3rd quarter. Signaturefd LLC now owns 10,034 shares of the medical research company's stock valued at $866,000 after acquiring an additional 142 shares during the period. NTV Asset Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $884,000. Farmers & Merchants Investments Inc. increased its holdings in Edwards Lifesciences by 0.6% in the 3rd quarter. Farmers & Merchants Investments Inc. now owns 134,493 shares of the medical research company's stock worth $11,609,000 after acquiring an additional 746 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its holdings in Edwards Lifesciences by 1.8% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company's stock worth $627,000 after acquiring an additional 132 shares in the last quarter. Finally, Inspire Investing LLC raised its stake in Edwards Lifesciences by 6.6% during the 3rd quarter. Inspire Investing LLC now owns 33,808 shares of the medical research company's stock worth $2,918,000 after acquiring an additional 2,088 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

EW has been the topic of several analyst reports. Rothschild & Co Redburn lifted their price target on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the company a "buy" rating in a report on Monday, July 27th. The Goldman Sachs Group upped their price target on shares of Edwards Lifesciences from $98.00 to $102.00 and gave the stock a "buy" rating in a research report on Tuesday, July 14th. Piper Sandler reissued an "overweight" rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. BTIG Research restated a "buy" rating and set a $110.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 11th. Finally, Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $89.15 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The firm has a fifty day moving average price of $88.05 and a 200 day moving average price of $86.65. Edwards Lifesciences Corporation has a fifty-two week low of $74.66 and a fifty-two week high of $96.29. The firm has a market cap of $51.33 billion, a price-to-earnings ratio of 51.23, a P/E/G ratio of 2.33 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences's revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares of the company's stock, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Annette Brüls sold 2,644 shares of the firm's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president owned 17,984 shares of the company's stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 5,045 shares of company stock valued at $451,596 in the last 90 days. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart's valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.